亚宝药业(600351) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥800,499,169.06, representing a year-on-year increase of 15.30%[5] - The net profit attributable to shareholders for the same period was ¥107,419,836.15, reflecting a significant increase of 50.47% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.1395, which is an increase of 50.47% year-on-year[6] - Total revenue for Q1 2023 reached ¥800,499,169.06, an increase of 15.3% compared to ¥694,295,635.07 in Q1 2022[17] - Operating profit for Q1 2023 was ¥130,496,444.86, up 48.4% from ¥87,848,278.81 in Q1 2022[18] - Net profit for Q1 2023 was ¥108,529,546.66, representing a 55% increase from ¥70,043,628.72 in Q1 2022[18] - Earnings per share for Q1 2023 were ¥0.1395, compared to ¥0.0927 in Q1 2022, reflecting a growth of 50.5%[19] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥94,425,180.27, marking an impressive increase of 88.76% year-on-year[5] - Operating cash inflow for Q1 2023 was CNY 699,369,435.86, an increase of 16.1% from CNY 602,384,142.98 in Q1 2022[20] - Net cash flow from operating activities for Q1 2023 was CNY 94,425,180.27, up 88.5% from CNY 50,025,100.38 in Q1 2022[21] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 711,175,799.49, compared to CNY 481,228,091.53 at the end of Q1 2022, representing a 47.7% increase[22] - The company reported a cash balance of RMB 761,097,151.88, up from RMB 668,503,421.96, indicating stronger liquidity[13] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,212,374,707.12, a 1.97% increase from the end of the previous year[6] - The total current assets amounted to RMB 2,060,915,179.43, an increase from RMB 1,954,333,997.61 as of December 31, 2022[13] - The total non-current assets decreased to RMB 2,151,459,527.69 from RMB 2,176,733,059.77, indicating a reduction in long-term investments[14] - Total liabilities increased to RMB 2,060,915,179.43, reflecting the company's ongoing financing activities[14] - Total liabilities decreased to ¥1,097,217,381.19 in Q1 2023 from ¥1,124,425,007.43 in Q1 2022, a reduction of approximately 2.4%[17] - Total equity increased to ¥3,115,157,325.93 in Q1 2023 from ¥3,006,642,049.95 in Q1 2022, marking a growth of about 3.6%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 56,133[11] - The largest shareholder, Shanshi Yabao Investment Group Co., Ltd., holds 94,300,000 shares, accounting for 12.25% of total shares[11] Expenses and Cost Management - Research and development expenses for Q1 2023 were ¥27,263,743.67, up from ¥25,593,278.84 in Q1 2022, indicating a 6.5% increase[17] - Sales expenses rose to ¥238,759,501.81 in Q1 2023, compared to ¥223,202,616.75 in Q1 2022, reflecting a growth of 7%[17] - The company reported a significant reduction in sales expenses, which decreased to ¥11,538,915.78 from ¥13,592,317.90 in Q1 2022, indicating improved cost management[25] - The company reported a decrease in financial expenses to ¥2,250,799.69 in Q1 2023 from ¥3,876,165.30 in Q1 2022, a reduction of approximately 42%[17] Government Subsidies - The company reported a significant increase in government subsidies recognized in profit or loss, which rose by 226.50% year-on-year[9] - Other income for Q1 2023 was ¥8,034,006.80, significantly higher than ¥2,460,643.90 in Q1 2022, representing a growth of 226.5%[17] Future Plans - The company plans to continue expanding its market presence and investing in new product development[25] - The company has not reported any significant new product developments or market expansions in the current quarter[12]